Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban

<div>Receiver operating curves of CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, CHA<sub>2</sub>DS<sub>2</sub>-VASc-RAF, and R<sub>2</sub>CHADS<sub>2</sub> for predicting LAAT and associated characteristics of that prediction in the rivaroxaban treatment group.</div>

Cardiology Research and Practice

fig2

Figure 2

Figure 2: Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban 

Figure 2 | Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban 